PT - JOURNAL ARTICLE AU - Olha Holubovska AU - Denisa Bojkova AU - Stefano Elli AU - Marco Bechtel AU - David Boltz AU - Miguel Muzzio AU - Xinjian Peng AU - Frederico Sala AU - Cesare Cosentino AU - Alla Mironenko AU - Jens Milde AU - Yuriy Lebed AU - Holger Stammer AU - Andrew Goy AU - Marco Guerrini AU - Lutz Mueller AU - Jindrich Cinatl AU - Victor Margitich AU - Aartjan J. W. te Velthuis TI - Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial AID - 10.1101/2021.01.05.21249237 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.05.21249237 4099 - http://medrxiv.org/content/early/2021/01/12/2021.01.05.21249237.short 4100 - http://medrxiv.org/content/early/2021/01/12/2021.01.05.21249237.full AB - Pandemic SARS-CoV-2 causes a mild to severe respiratory disease called Coronavirus Disease 2019 (COVID-19). Control of SARS-CoV-2 spread will depend on vaccine-induced or naturally acquired protective herd immunity. Until then, antiviral strategies are needed to manage COVID-19, but approved antiviral treatments, such as remdesivir, can only be delivered intravenously. Enisamium (laboratory code FAV00A, trade name Amizon®) is an orally active inhibitor of influenza A and B viruses in cell culture and clinically approved in countries of the Commonwealth of Independent States. Here we show that enisamium can inhibit SARS-CoV-2 infections in NHBE and Caco-2 cells. In vitro, the previously identified enisamium metabolite VR17-04 directly inhibits the activity of the SARS-CoV-2 RNA polymerase. Docking and molecular dynamics simulations suggest that VR17-04 prevents GTP and UTP incorporation. To confirm enisamium’s antiviral properties, we conducted a double-blind, randomized, placebo-controlled trial in adult, hospitalized COVID-19 patients, which needed medical care either with or without supplementary oxygen. Patients received either enisamium (500 mg per dose) or placebo for 7 days. A pre-planned interim analysis showed in the subgroup of patients needing supplementary oxygen (n = 77) in the enisamium group a mean recovery time of 11.1 days, compared to 13.9 days for the placebo group (log-rank test; p=0.0259). No significant difference was found for all patients (n = 373) or those only needing medical care (n = 296). These results thus suggest that enisamium is an inhibitor of SARS-CoV-2 RNA synthesis and that enisamium treatment shortens the time to recovery for COVID-19 patients needing oxygen.Significance statement SARS-CoV-2 is the causative agent of COVID-19. Although vaccines are now becoming available to prevent SARS-CoV-2 spread, the development of antivirals remains necessary for treating current COVID-19 patients and combating future coronavirus outbreaks. Here, we report that enisamium, which can be administered orally, can prevent SARS-CoV-2 replication and that its metabolite VR17-04 can inhibit the SARS-CoV-2 RNA polymerase in vitro. Moreover, we find that COVID-19 patients requiring supplementary oxygen, recover more quickly than patients treated with a placebo. Enisamium may therefore be an accessible treatment for COVID-19 patients.Competing Interest StatementV.M. and A.G. are employees of Farmak Public Joint Stock Company, Kiev, Ukraine. Part of the research was funded by Farmak Public Joint Stock Company, Kiev, Ukraine.Clinical TrialNCT04682873Funding StatementA.J.W.t.V is supported by joint Wellcome Trust and Royal Society grant 206579/Z/17/Z and the National Institutes of Health grant R21AI147172. Part of this research was funded by Farmak Public Joint Stock Company, Kiev, Ukraine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Commission of the Regional Clinical Hospital of Ivano-Frankivsk Regional Council on 12.05.2020. The registration number of the study in ClinicalTrials.gov is NCT04682873.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data will be made available on ClinicalTrials.gov via number NCT04682873 and via the provided supplemental information.